Meaningful digital mobility outcomes for people with Parkinson's disease: Insights grounded in diverse lived experience
Background Digital mobility outcomes (DMOs) have been cited as potential clinical endpoints for trials in Parkinson's disease (PD). Current evidence from the Mobilise-D consortium suggests that selected DMOs are technically valid, with emerging research on their clinical validity. However, regulatory qualification of D...